- Home
- PHVS vs CGEM Comparison
PHVS vs CGEM Comparison
Compare PHVS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CGEM
- Stock Information
- Founded
- PHVS 2015
- CGEM 2016
- Country
- PHVS Netherlands
- CGEM United States
- Employees
- PHVS N/A
- CGEM N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- CGEM Health Care
- Exchange
- PHVS Nasdaq
- CGEM Nasdaq
- Market Cap
- PHVS 1.0B
- CGEM 730.2M
- IPO Year
- PHVS 2021
- CGEM 2021
- Fundamental
- Price
- PHVS $18.54
- CGEM $12.39
- Analyst Decision
- PHVS Strong Buy
- CGEM Strong Buy
- Analyst Count
- PHVS 5
- CGEM 7
- Target Price
- PHVS $40.60
- CGEM $31.67
- AVG Volume (30 Days)
- PHVS 66.5K
- CGEM 546.1K
- Earning Date
- PHVS 11-13-2024
- CGEM 11-07-2024
- Dividend Yield
- PHVS N/A
- CGEM N/A
- EPS Growth
- PHVS N/A
- CGEM N/A
- EPS
- PHVS N/A
- CGEM N/A
- Revenue
- PHVS N/A
- CGEM N/A
- Revenue This Year
- PHVS N/A
- CGEM N/A
- Revenue Next Year
- PHVS N/A
- CGEM N/A
- P/E Ratio
- PHVS N/A
- CGEM N/A
- Revenue Growth
- PHVS N/A
- CGEM N/A
- 52 Week Low
- PHVS $15.37
- CGEM $10.00
- 52 Week High
- PHVS $33.00
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- PHVS 42.23
- CGEM 47.96
- Support Level
- PHVS $18.18
- CGEM $11.75
- Resistance Level
- PHVS $19.88
- CGEM $12.95
- Average True Range (ATR)
- PHVS 1.17
- CGEM 0.76
- MACD
- PHVS 0.08
- CGEM 0.19
- Stochastic Oscillator
- PHVS 23.92
- CGEM 77.69
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.